Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from Genmab ( (GMAB) ).
On September 10, 2025, Genmab A/S announced updates to its Articles of Association, authorizing the Board of Directors to increase the company’s share capital and issue warrants and convertible debt instruments. These changes aim to provide financial flexibility and support the company’s growth strategy, impacting stakeholders by potentially diluting existing shares but also offering opportunities for investment and expansion.
The most recent analyst rating on (GMAB) stock is a Buy with a $28.00 price target. To see the full list of analyst forecasts on Genmab stock, see the GMAB Stock Forecast page.
Spark’s Take on GMAB Stock
According to Spark, TipRanks’ AI Analyst, GMAB is a Outperform.
Genmab’s overall stock score is driven by strong earnings call results and positive technical indicators, highlighting robust growth prospects and market momentum. The company’s solid financial performance, despite recent revenue and cash flow challenges, supports its stability. Valuation metrics suggest the stock is undervalued, offering potential upside. The absence of significant corporate events does not impact the score.
To see Spark’s full report on GMAB stock, click here.
More about Genmab
Genmab A/S is a Danish biotechnology company focused on medical research, production, and sale of related products. The company’s primary market focus is on developing innovative antibody therapeutics for the treatment of cancer and other serious diseases.
Average Trading Volume: 1,370,850
Technical Sentiment Signal: Buy
Current Market Cap: $16.76B
See more insights into GMAB stock on TipRanks’ Stock Analysis page.